登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H20N2O6
化学文摘社编号:
分子量:
360.36
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
尼群地平, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
SMILES string
CCOC(=O)C1=C(C)NC(C)=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OC
InChI key
PVHUJELLJLJGLN-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
nitrendipine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
Application
Nitrendipine for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
存储类别
11 - Combustible Solids
wgk
WGK 1
A Zanchetti
Journal of cardiovascular pharmacology, 12 Suppl 4, S80-S85 (1988-01-01)
There is evidence from several studies of the clinical usefulness of an antihypertensive regimen combining a calcium antagonist and an angiotensin converting enzyme (ACE) inhibitor. The mechanisms of this mutual potentiation between agents of these two classes are probably numerous.
E P Mac Carthy
Journal of cardiovascular pharmacology, 12 Suppl 4, S76-S79 (1988-01-01)
The combination of a beta-adrenoceptor-blocking drug with the dihydropyridine calcium channel antagonist, nitrendipine, has particular therapeutic advantages in the management of hypertension. The beta-blocker reduces any reflex increases in sympathetic nervous system and renin-angiotensin system activity that result from the
U L Hulthén et al.
Journal of cardiovascular pharmacology, 12 Suppl 4, S11-S15 (1988-01-01)
The dihydropyridine calcium antagonist nitrendipine offers a pathophysiologically based antihypertensive treatment with a potent dilation of resistance vessels, increased arterial compliance, and an acute natriuretic/diuretic response. Prolonged nitrendipine treatment in essential hypertension is not associated with stimulation of the sympathetic
S K Vanov et al.
Angiology, 39(1 Pt 2), 113-122 (1988-01-01)
To assess the safety of the calcium channel blocker nitrendipine, data from 61 clinical studies conducted in the United States and involving 1,245 patients were reviewed. The drug appeared to be tolerated in the majority of patients and the dropout
B N Trost et al.
Journal of cardiovascular pharmacology, 6 Suppl 7, S986-S995 (1984-01-01)
Some calcium antagonists, including nitrendipine, were noted to cause a dose-dependent and reversible inhibition of insulin release in certain animal models. Therefore, it is important to know the effects of clinical treatment with calcium antagonists in nondiabetic or diabetic man.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持